Fritz Offner

Fritz Offner

UNVERIFIED PROFILE

Are you Fritz Offner?   Register this Author

Register author
Fritz Offner

Fritz Offner

Publications by authors named "Fritz Offner"

Are you Fritz Offner?   Register this Author

78Publications

2503Reads

33Profile Views

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma.

Front Genet 2019 15;10:740. Epub 2019 Aug 15.

Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2019.00740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704229PMC
August 2019

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Leukemia 2019 May 14. Epub 2019 May 14.

Department of Medicine V, University Hospital Heidelberg, Department of Molecular Therapy in Haematology & Oncology, NCT/DKFZ, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0475-zDOI Listing
May 2019

Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies.

PLoS One 2018 8;13(5):e0197000. Epub 2018 May 8.

Receptor Research Laboratories, Nuclear Receptor Lab (NRL) and Cytokine Receptor Lab (CRL), Department for Biomolecular Medicine, VIB-UGent Center for Medical Biotechnology, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197000PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940183PMC
August 2018

Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.

J Proteomics 2018 05 13;179:17-29. Epub 2018 Feb 13.

Laboratory of Protein Chemistry, Proteomics and Epigenetic Signalling (PPES), Department of Biomedical Sciences, University of Antwerp (UA), Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2018.02.013DOI Listing
May 2018

Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies.

Oncotarget 2017 Dec 30;8(65):109675-109691. Epub 2017 Nov 30.

Receptor Research Laboratories, Nuclear Receptor Lab (NRL) and Cytokine Receptor Lab (CRL), VIB-UGent Center for Medical Biotechnology, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752551PMC
December 2017

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

J Clin Oncol 2016 10;34(30):3609-3617

Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7295DOI Listing
October 2016

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

J Clin Oncol 2016 08 13;34(22):2575-82. Epub 2016 Jun 13.

Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7163DOI Listing
August 2016

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2016 07 23;34(21):2484-92. Epub 2016 May 23.

Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7171DOI Listing
July 2016

Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments.

Oncoscience 2016 27;3(7-8):188-202. Epub 2016 Jul 27.

Laboratory of Experimental Cancer Research (LECR), Department of Radiation Oncology & Experimental Cancer Research, Ghent University, Gent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043069PMC
July 2016

Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation.

Br J Cancer 2016 Mar 25;114(6):704-12. Epub 2016 Feb 25.

Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800300PMC
March 2016

Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma.

Eur J Radiol 2016 Feb 2;85(2):373-82. Epub 2015 Dec 2.

Ghent University, Department of Radiology, MR -1K12, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2015.11.040DOI Listing
February 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Ann Hematol 2015 Apr 30;94(4):633-41. Epub 2015 Jan 30.

Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2269-8DOI Listing
April 2015

Impact of organ dysfunction on mortality in ICU patients with hematologic malignancies.

Intensive Care Med 2010 Oct 18;36(10):1744-50. Epub 2010 May 18.

Department of Public Health and Health Economics, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00134-010-1903-8DOI Listing
October 2010

The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562.

Mol Nutr Food Res 2010 Jun;54(6):823-32

Department of Hematology, University Hospital Ghent, De Pintelaan 185, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mnfr.200900186DOI Listing
June 2010

The impact of the initial ventilatory strategy on survival in hematological patients with acute hypoxemic respiratory failure.

J Crit Care 2010 Mar 13;25(1):30-6. Epub 2009 Aug 13.

Department of Intensive Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcrc.2009.02.016DOI Listing
March 2010

Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia.

Anticancer Res 2009 Oct;29(10):3797-805

Ghent University Hospital, Department of Hematology, De Pintelaan 185, 1P7, B-9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
October 2009

Chronic lymphocytic leukaemia.

Anticancer Res 2009 Feb;29(2):605-15

Department of Haematology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
February 2009

Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies.

Intensive Care Med 2008 May 24;34(5):847-55. Epub 2008 Jan 24.

Department of Intensive Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00134-008-1002-2DOI Listing
May 2008

Levetiracetam and bleeding disorders.

Acta Neurol Belg 2007 Dec;107(4):97-102

Department of Neurology, Reference Center for Refractory Epilepsy, Ghent University Hospital, Belgium.

View Article

Download full-text PDF

Source
December 2007

Review. The endoplasmic reticulum: a target for new anticancer drugs.

In Vivo 2007 Mar-Apr;21(2):215-26

Department of Hematology, Ghent University Hospital, Ghent, Belgium.

View Article

Download full-text PDF

Source
July 2007

Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.

Clin Chem 2007 Feb 7;53(2):204-12. Epub 2006 Dec 7.

Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2006.076331DOI Listing
February 2007

EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient.

Am J Hematol 2006 Sep;81(9):706-12

Department of Hematology, Ghent University Hospital, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.20712DOI Listing
September 2006

Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status.

Cytometry B Clin Cytom 2006 Jul;70(4):302-8

Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.20122DOI Listing
July 2006

Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit.

Intensive Care Med 2006 Jan 25;32(1):93-9. Epub 2005 Nov 25.

Department of Intensive Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00134-005-2836-5DOI Listing
January 2006

Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).

Int J Oncol 2005 Oct;27(4):1113-24

Laboratory of Physiological Chemistry, Christian de Duve Institute of Cellular Pathology, UCL-ICP 7539, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
October 2005

Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism.

Mol Nutr Food Res 2005 Sep;49(9):844-50

Department of Hematology, Ghent University Hospital, Gent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mnfr.200500045DOI Listing
September 2005

Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies.

Nephrol Dial Transplant 2005 Mar 25;20(3):552-8. Epub 2005 Jan 25.

Department of Internal Medicine, Intensive Care Medicine, Medical Intensive Care Unit, 12K12IB, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ndt/gfh637DOI Listing
March 2005